Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWC202310
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
01
Overview
DWC202310 is a small molecule drug developed by Daewoong Pharmaceutical. It has been studied in combination with another investigational agent, DWC202311, in bioequivalence and pharmacokinetic studies involving healthy volunteers. The primary focus of these studies is to compare the pharmacokinetics and safety profile of DWJ1558 (another compound) when administered alone versus co-administration with DWC202310 and DWC202311. Specific details regarding the mechanism of action, therapeutic targets, or intended indications for DWC202310 have not been disclosed in publicly available sources as of June 26, 2025[2][4].
- Other names
- DWC202310DWC-202310DWC 202310
Beyond the preview
Go deeper on DWC202310.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWC202310.